advertisement
Lu F 34
Showing records 1 to 25 | Display all abstracts from Lu F117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Bacharach J
American Journal of Ophthalmology 2024; 263: 23-34
117010 Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner
He C
Journal of Neuroinflammation 2024; 21: 43
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Wang TH
Clinical Ophthalmology 2024; 18: 2093-2106
117247 Association of plasma lactoferrin levels with disease severity in glaucoma patients
Wang Z
Frontiers in medicine 2024; 11: 1385358
117010 Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner
Peng K
Journal of Neuroinflammation 2024; 21: 43
117247 Association of plasma lactoferrin levels with disease severity in glaucoma patients
Liu D
Frontiers in medicine 2024; 11: 1385358
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Brubaker JW
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Aung T; Lu DW
Clinical Ophthalmology 2024; 18: 2093-2106
117010 Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner
Zhu X
Journal of Neuroinflammation 2024; 21: 43
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Evans DG
American Journal of Ophthalmology 2024; 263: 23-34
117247 Association of plasma lactoferrin levels with disease severity in glaucoma patients
Yuan H; Li A
Frontiers in medicine 2024; 11: 1385358
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Lu F
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
George R
Clinical Ophthalmology 2024; 18: 2093-2106
117010 Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner
Wang Z
Journal of Neuroinflammation 2024; 21: 43
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Senthil S
Clinical Ophthalmology 2024; 18: 2093-2106
117247 Association of plasma lactoferrin levels with disease severity in glaucoma patients
Wang J
Frontiers in medicine 2024; 11: 1385358
117010 Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner
Xiu W
Journal of Neuroinflammation 2024; 21: 43
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Odani-Kawabata N
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Lu F
Clinical Ophthalmology 2024; 18: 2093-2106
117247 Association of plasma lactoferrin levels with disease severity in glaucoma patients
Zhu X
Frontiers in medicine 2024; 11: 1385358
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Yamabe T
American Journal of Ophthalmology 2024; 263: 23-34
117010 Th1 cells contribute to retinal ganglion cell loss in glaucoma in a VCAM-1-dependent manner
Zhang G
Journal of Neuroinflammation 2024; 21: 43
117247 Association of plasma lactoferrin levels with disease severity in glaucoma patients
Xiu W
Frontiers in medicine 2024; 11: 1385358
117008 Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Wirta DL
American Journal of Ophthalmology 2024; 263: 23-34
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Odani-Kawabata N; Park KH
Clinical Ophthalmology 2024; 18: 2093-2106
